Stamford, US Aug 22, 2025 (Issuewire.com) - Harrison Global Holdings Inc., formerly BloomZ Inc., has signed a strategic international partnership with Biotree Co., Ltd., a Korean biotech pioneer developing the worlds first natural product-based drug for metabolic syndrome.
Why This Matters to Investors
- Biotrees PH-100 has completed Phase 1 trials in the U.S. and Phase 2A trials in Korea, showing strong results in reducing inflammation and improving cardiovascular health.
- The drug is expected to receive conditional approval by mid-2026, opening up prescription-only revenue streams.
- Biotree is the first Korean firm to extract Seapolynol from Gamtae seaweedused in health foods, cosmetics, and pharmaceuticals.
- Harrison Global will help expand Biotrees reach into the U.S., Japan, China, and broader Asia through joint ventures, licensing, and localized development.
Strategic Synergy
This partnership blends Harrisons entertainment and youth engagement expertise with Biotrees biotech innovation, creating a hybrid growth engine across lifestyle, wellness, and media sectors.
Executive Insight
"Were thrilled to contribute to global health by supporting Biotrees breakthrough treatment," said Ryoshin Nakade, Co-CEO of Harrison Global. "This partnership reflects our commitment to innovation and international expansion."
Enrique Vargas
More On Newsinterestcorp ::
- Donegal Abbey Private Equity Provides $58M Construction Financing for 500-Key Marriott Resort in Kissimmee, Florida
- CQDJ China’s Leading Fiberglass Roving Manufacturer, Expands Global Reach at Major Composites Expos
- John Adeiza, FNP-C: Delivering Compassionate Care with Restore Medical Group
- The Traveler Launches as an Open Travel Publication for Global Storytellers
- Netanya to Ignite Dancefloors Worldwide with New Single “Meant to Be”
(845) 288-0020
Source :Harrison Global Holdings
This article was originally published by IssueWire. Read the original article here.